Raymond James Financial Services Advisors’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Raymond James Financial Services Advisors’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-64	Closed	-$8K	–	2971
2019 Q3	$8K	Hold	64	–	–	﹤0.01%	2782
2019 Q2	$19K	Hold	64	–	–	﹤0.01%	2795
2019 Q1	$29K	Hold	64	–	–	﹤0.01%	2736
2018 Q4	$29K	Buy	+64	New	+$39.7K	﹤0.01%	2499

Other funds holding HTGM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

CPA

Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HWM

HighMark Wealth Management St. Paul, Minnesota $246M AUM 35.95% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Raymond James Financial Services Advisors's HTGM Position: Q4 2019 in Review

Raymond James Financial Services Advisors sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2019, closing a stake of 64 shares — an estimated $8K sold.

Raymond James Financial Services Advisors first reported a position in HTGM in Q4 2018 and held it in 4 quarters. The position peaked at $29K in Q1 2019. 27 funds tracked by Wall St. Rank hold HTGM as of Q4 2019.

Raymond James Financial Services Advisors reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Raymond James Financial Services Advisors sold 64 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2019, an estimated $8K.
Raymond James Financial Services Advisors first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q4 2018 and held it in 4 quarters.
Raymond James Financial Services Advisors's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $29K in Q1 2019.
27 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2019.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.